Last Updated: 18/06/2024
Development of fosmidomycin and clindamycin, in a fixed dose combination, for the treatment of acute uncomplicated Plasmodium falciparum malaria
Objectives
The primary aim of the project is to develop fosmidomycin and clindamycin, in a fixed dose combination, for registration as a novel treatment for acute uncomplicated Plasmodium falciparum malaria in children. By implication, this will also include the treatment of multi-drug resistant P. falciparum malaria. Following registration, development will be explored for intermittent preventive treatment (IPT) for malaria in pregnancy.
The combination of fosmidomycin and clindamycin constitutes a novel approach to the chemotherapy of malaria and incorporates a unique mechanism of action. It will provide an alternative to artemisinin-containing therapies (ACTs) in the event of the development of resistance to ACTs, since the sites and modes of action of fosmidomycin and clindamycin (apicoplast) are so distinct from targets suggested for conventional ACTs.
Jan 2010 — Jan 2013
$7.06M
Related Resources
